<p>Embecta is now fully independent from Becton Dickinson & Co. Devdatt Kurdikar, Embecta's CEO talks about what that means going forward and his plans for the company.  With its rich pedigree and newly-independent status, Embecta is truly the new/old kid on the block in diabetes care.</p>

Embecta is now fully independent from Becton Dickinson & Co. Devdatt Kurdikar, Embecta's CEO talks about what that means going forward and his plans for the company. With its rich pedigree and newly-independent status, Embecta is truly the new/old kid on the block in diabetes care.

<p>Embecta is now fully independent from Becton Dickinson &amp; Co. Devdatt Kurdikar, Embecta's CEO talks about what that means going forward and his plans for the company.&nbsp;&nbsp;With its rich pedigree and newly-independent status, Embecta is truly the new/old kid on the block in diabetes care.</p>

Let's Talk Medtech: Why Embecta Stands Out in Diabetes Care

MD+DI editors discuss current trends in the medical device and diagnostics industry, and point out developments to watch in the coming months.

Share Let's Talk Medtech: Why Embecta Stands Out in Diabetes Care

Sign up to save your podcasts

Let's Talk Medtech: Why Embecta Stands Out in Diabetes Care

Let's Talk Medtech: Why Embecta Stands Out in Diabetes Care

More shows like Let’s Talk Medtech

The Daily